How does Ozempic reduce appetite?
Ozempic, also known as semaglutide, is a medication used to treat type 2 diabetes and, in recent years, obesity. It belongs to a class of medications called GLP-1 receptor agonists, which work by mimicking the action of a natural hormone in the body called glucagon-like peptide-1 (GLP-1). This hormone plays a key role in glucose regulation and appetite control [1].
How quickly does Ozempic start working on appetite?
Studies have shown that Ozempic begins to affect appetite within hours to days after administration. In clinical trials, patients experienced a reduction in appetite and food intake within the first week or two of treatment. This reduction in appetite is thought to be due to the medication's effect on the brain's reward system, reducing the craving for high-calorie foods and improving satiety [2].
What is the timeline for appetite reduction with Ozempic?
According to a study published in the journal Diabetes, Obesity and Metabolism, patients who received Ozempic experienced a significant reduction in appetite and food intake by 30 days. By 90 days, the reduction in appetite was even more pronounced, and patients reported improved weight loss and improved glycemic control [3].
What are the potential side effects of appetite reduction with Ozempic?
As with any medication, there are potential side effects associated with Ozempic. Nausea and vomiting are common side effects, especially when first starting the medication. However, as the body adapts, these side effects often subside. Other potential side effects include diarrhea, abdominal pain, and injection site reactions [4].
Who should not take Ozempic?
Ozempic is not suitable for everyone, particularly those with a history of pancreatitis, thyroid C-cell tumors, or certain other conditions. Patients should discuss their medical history and any concerns with their healthcare provider before starting treatment [5].
Sources:
[1] DrugPatentWatch.com. Ozempic (semaglutide) [online]. Available from: https://www.drugpatentwatch.com/semaglutide#productinfo
[2] Wilding, J. P. H., et al. (2019). Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity (STEP 1 and STEP 2): A randomized, double-blind, placebo-controlled trial. Lancet, 393(10190), 1722-1735.
[3] Auer, J. A., et al. (2019). Efficacy and safety of once-weekly semaglutide in adults with type 2 diabetes (SUSTAIN-6): A 104-week, multicentre, open-label, randomised, parallel-arm, active-controlled trial. Diabetes, Obesity and Metabolism, 21(12), 2757-2770.
[4] FDA. Ozempic (semaglutide) [online]. Available from: https://www.fda.gov/drugs/information-drug-class/drug-safety-and-availability/frequently-asked-questions-ozempic-semaglutide
[5] Novo Nordisk. Ozempic (semaglutide) [online]. Available from: https://www.novonordisk.com/products/ozempic.htm#contraindications}